Ovid Therapeutics Inc. (NASDAQ: OVID)

Ovid Therapeutics Inc., a company known by its stock symbol OVID, operates in the pharmaceutical industry with a focus on developing novel small molecule medicines for rare and orphaned neurological disorders. The company's primary business activities are centered on improving the lives of people affected by certain epilepsies and brain conditions with seizure symptoms.

Ovid's main source of revenue comes from its pipeline of small molecule programs, which includes three primary products: Soticlestat, OV888 (GV101), and OV329. These products are designed to treat a variety of neurological disorders, such as resistant epilepsies, cerebral cavernous malformations (CCMs), and other neurological disorders. Soticlestat, a novel cholesterol 24 hydroxylase (CH24) inhibitor, is being developed in partnership with Takeda Company Limited and has the potential to become a first-in-class medicine targeting the metabolism of cholesterol in the brain. OV888 (GV101), a highly selective inhibitor of rho-associated coiled-coil containing protein kinase 2 (ROCK2), is being developed as a potential first-in-class medicine to treat CCMs. OV329, a highly potent next-generation GABA-aminotransferase inhibitor, is being developed as a potential first-in-class medicine to treat epilepsy and other neurological disorders.

Ovid's position within the industry is strengthened by its focus on developing novel small molecule medicines for rare and orphaned neurological disorders. The company's competitive advantages include its expertise in understanding mechanisms of action that underlie seizures and shaping potential therapies to treat rare epilepsies and disorders with seizures. Ovid's pipeline of potential first-in-class or best-in-class mechanisms differentiates it from other companies in the industry.

The primary customers for Ovid's products are patients with rare and orphaned neurological disorders, including epilepsy, Lennox-Gastaut syndrome, and Dravet syndrome. These patients often experience significant unmet medical need and limited treatment options, making Ovid's products particularly valuable.

In addition to the products mentioned above, Ovid has a few more in its pipeline. OV350 is a potential first-in-class direct activator of the central nervous system (CNS) specific K-Cl co-transporter (KCC2) being developed as a potential medicine to treat epilepsy and other neurological disorders. The product is expected to file its first investigational new drug application (IND) in 2024.